Xeroderma pigmentosum (XP) is a rare, autosomal recessive disorder characterized by extreme sensitivity to ultraviolet (UV) radiation, leading to severe skin and ocular manifestations, premature aging, and an increased risk of developing malignant tumors. The disorder is caused by defects in nucleotide excision repair (NER), a crucial DNA repair mechanism responsible for correcting UV-induced DNA damage. XP is clinically diagnosed in early childhood, with an incidence of approximately 1 in 250,000 individuals in the United States. The condition requires lifelong management to reduce UV-induced damage and prevent malignancies.
Genetic Basis and Molecular Pathophysiology
XP arises from mutations in one of seven genes involved in the NER pathway: XPA, XPB, XPC, XPD, XPE, XPF, and XPG. These genes encode proteins responsible for identifying and repairing UV-induced DNA damage, such as thymine dimers. A failure to repair this damage leads to mutations that accumulate in the skin and other tissues, causing early onset of skin changes, premature aging, and an increased risk of skin cancer.
NER is a multi-step process that includes the recognition of DNA lesions, excision of the damaged strand, and the synthesis of a new DNA strand. Mutations in the XP genes compromise this process, resulting in hypersensitivity to UV radiation and impaired cellular response to DNA damage. The condition follows an autosomal recessive inheritance pattern, meaning individuals with XP inherit two mutated alleles, one from each parent, both of whom are typically asymptomatic carriers. XP is more prevalent in populations of North African, Japanese, and Mediterranean descent.
Clinical Manifestations
The clinical features of XP can be categorized into three main domains: cutaneous, ocular, and neurological manifestations.
Cutaneous Manifestations
Stage 1 (Infancy to Early Childhood): The initial signs of XP typically appear before the age of 2 years, with the onset of diffuse erythema, scaling, and freckle-like hyperpigmentation in sun-exposed areas such as the face. These changes are exacerbated by UV exposure and can temporarily improve during winter months but become permanent over time.
Stage 2 (Poikiloderma): As the disease progresses, patients develop poikiloderma, characterized by skin atrophy, telangiectasias (small blood vessels), and mottled hyperpigmentation and hypopigmentation. These changes may affect both sun-exposed and non-exposed areas of the skin, including the buccal mucosa.
Stage 3 (Malignancies): By age 4-5 years, individuals with XP are at a significantly increased risk for the early onset of skin malignancies, including squamous cell carcinoma, basal cell carcinoma, malignant melanoma, and fibrosarcoma. These tumors typically arise in sun-exposed areas but may also occur in non-exposed regions.
Ocular Manifestations
Approximately 80% of individuals with XP experience ocular complications, including photophobia, conjunctivitis, corneal opacities, and dry eye syndrome. Over time, more severe complications such as cataracts, retinal degeneration, and vision loss may occur, highlighting the need for regular ophthalmologic monitoring.
Neurological Manifestations
Neurological involvement is present in 20% of XP patients, especially those with mutations in XPA, XPD, and XPC genes. Neurological symptoms include microcephaly, spasticity, ataxia, hyporeflexia, chorea, motor neuron degeneration, and segmental demyelination. In severe cases, XP can present with supranuclear ophthalmoplegia or sensorineural deafness. The combination of neurological and cutaneous features in some XP patients significantly impacts their quality of life. De Sanctis-Cacchione syndrome, a variant of XP, is characterized by severe neurological deficits, including mental retardation, cerebellar ataxia, dwarfism, and hypogonadism.
Diagnosis
The diagnosis of XP is primarily clinical, based on early signs of severe photosensitivity, skin changes, and a family history of consanguinity. Molecular genetic testing is required for definitive diagnosis, with gene sequencing and complementation studies used to identify mutations in the XP-related genes. Cellular hypersensitivity to UV radiation and chromosomal breakage studies are also used to confirm the diagnosis. Prenatal diagnosis is possible through amniocentesis or chorionic villus sampling, which can detect mutations in the fetus.
Treatment and Management
Currently, there is no cure for XP, and the goal of treatment is to prevent further UV-induced DNA damage and minimize the risk of developing malignancies.
- Sun Protection
Strict Sun Avoidance: The most important aspect of managing XP is minimizing UV exposure. This involves wearing protective clothing, wide-brimmed hats, and UV-blocking sunglasses. Sunscreens with high SPF (50 or greater) should be used on exposed areas, although they do not provide complete protection.
UV-Proofed Living Spaces: Patients should limit outdoor activity during daylight hours and use UV-protective window films and specialized lighting in homes and schools to reduce indoor UV exposure.
- Dermatologic Surveillance and Tumor Detection
Regular dermatologic evaluations are essential for early detection of skin malignancies. Cryotherapy, electrosurgery, and surgical excision are common treatment options for early-stage tumors. Laser therapy may be used for cosmetic concerns, including pigmentation changes and scarring. - Ophthalmologic and Neurologic Management
Ophthalmologic care is critical for managing ocular complications, including cataracts and corneal opacities. Patients should undergo routine eye exams to monitor for vision-threatening conditions.
Neurological management includes supportive care, such as physical therapy, speech therapy, and occupational therapy, to improve motor function and quality of life.
- Gene Therapy and Experimental Treatments
- Gene therapy for XP is still in the experimental phase, with research focused on using gene editing technologies like CRISPR-Cas9 to restore the function of defective repair genes. Although this approach holds promise, it is not yet available for clinical use.
Prognosis
The prognosis of XP varies based on the severity of the disease and the presence of neurological symptoms. Early detection, strict sun protection, and regular dermatologic monitoring can significantly improve outcomes. However, XP is a progressive disorder, and individuals often experience a shortened lifespan due to the early onset of malignancies. Neurological involvement, particularly in cases like De Sanctis-Cacchione syndrome, may further limit lifespan and quality of life.
Conclusion
Xeroderma pigmentosum is a rare but serious genetic disorder that requires lifelong management to prevent further UV-induced DNA damage and minimize the risk of malignancies. With ongoing research into gene therapy and improved supportive care, the outlook for individuals with XP may improve in the future. Early diagnosis, strict sun protection, and regular monitoring are key to managing the condition and improving patient outcomes.
References
Bolognia, J. L., Jorizzo, J. L., & Schaffer, J. V. (2012). Dermatology (3rd ed.). Elsevier Saunders.
Brash, D. E., et al. (2011). DNA repair defects and skin cancer: The xeroderma pigmentosum story. Journal of Investigative Dermatology, 131(8), 1812-1818. https://doi.org/10.1038/jid.2011.135
Brooks, P. J., et al. (2021). DNA repair and skin cancer. Cellular and Molecular Life Sciences, 78(1), 1-15. https://doi.org/10.1007/s00018-020-03679-9
DiGiovanna, J. J., & Kraemer, K. H. (2012). Xeroderma pigmentosum: Clinical features, diagnosis, and management. Journal of the American Academy of Dermatology, 66(5), 853-867. https://doi.org/10.1016/j.jaad.2011.07.010
Kraemer, K. H., et al. (2007). The xeroderma pigmentosum (XP) group A gene: Function, structure, and genetics. Journal of Investigative Dermatology, 127(10), 2417-2426. https://doi.org/10.1038/sj.jid.5700917
Miller, R. W., Pollard, J. D., & Nichols, W. (2020). Advances in gene therapy for xeroderma pigmentosum: Current perspectives and future directions. Genetic Therapy Review, 13(2), 115-122. https://doi.org/10.1111/gt.1325
Nagarajan, N., et al. (2016). Malignant melanoma in xeroderma pigmentosum: A review of the literature. Journal of Dermatology, 43(2), 169-178. https://doi.org/10.1111/1346-8138.13288
Pellacani, G., et al. (2014). Ocular findings in xeroderma pigmentosum: A retrospective study of 37 patients. Graefe’s Archive for Clinical and Experimental Ophthalmology, 252(7), 1139-1145. https://doi.org/10.1007/s00417-014-2670-9
Rosenberg, P. S., et al. (2015). The epidemiology of xeroderma pigmentosum. Journal of Investigative Dermatology, 135(5), 1203-1211. https://doi.org/10.1038/jid.2014.459
Sasaki, T., et al. (2013). Xeroderma pigmentosum: The molecular basis of the disease. Dermatologic Clinics, 31(3), 409-416. https://doi.org/10.1016/j.det.2013.02.008
Tan, A., et al. (2014). Prenatal diagnosis of xeroderma pigmentosum: Experience in a tertiary center. American Journal of Obstetrics and Gynecology, 210(5), 482.e1-482.e6. https://doi.org/10.1016/j.ajog.2013.10.002
